Drug
Onc206
Onc206: highest development phase Phase 2, developed by Jazz Pharmaceuticals. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Jazz Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ONC206 NCT07282587 | Phase 2 | Advanced Pheochromocytoma and Paraganglioma |
| ONC206 NCT04732065 | Phase 1 | Diffuse Midline Glioma (DMG) |
| ONC206 NCT04541082 | Phase 1 | Central Nervous System Neoplasms |
Latest
Follow Onc206 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.